<DOC>
	<DOC>NCT02003417</DOC>
	<brief_summary>This study will evaluate the proportion of prostate cancer patients receiving external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT) with controlled blood sugars (fasting glucose and hemoglobin A1c), blood pressure, and cholesterol profile (total cholesterol, LDL, HDL, triglycerides) at baseline, 3 months, and 12 months after completing radiation treatment. In addition, receipt of guideline-recommended cardiovascular, primary and preventive care as well as patient-reported quality of life and satisfaction with care among these patients will be evaluated at baseline and 12 months.</brief_summary>
	<brief_title>Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologicallyconfirmed, nonmetastatic prostate cancer Patients who will receive external beam radiation treatment with androgen deprivation therapy (total ADT duration &gt; 3 months) for curative treatment, either in the definitive or postprostatectomy setting Patients who have a primary care provider Informed consent obtained and signed Ability to read and write English Age &gt;= 18 No mental incompetence which would preclude completion of questionnaires Prior cancer, pelvic radiation treatment or chemotherapy Patients who do not have a primary care provider Prior ADT Mental incompetence which would preclude completion of questionnaires Unable to read and write English</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>External beam radiation treatment</keyword>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>Definitive treatment</keyword>
	<keyword>Cardiovascular risk factors</keyword>
	<keyword>Quality of life</keyword>
</DOC>